Jump to a section on this page:
Our lab is actively collaborating to develop reproducible aerosol models of delivery and answer longstanding biological questions about phage treatment in vivo.
This project is designed to develop an efficacious and durable prophylactic anti-NTM candidate targeted towards individuals at risk for developing NTM-LD.
Here we propose a more focused and translational screen of therapeutic vaccine candidates designed to be used in conjunction with drug treatment for post-primary tuberculosis.
This study is a Phase 1, randomized, blinded, placebo controlled, dose escalation clinical trial to evaluate the safety, tolerability, and immunogenicity of the Sm-p80 + GLA-SE vaccine candidate in 48 healthy adults.
